OakChart

Design Therapeutics Inc

DSGNHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

10.77+0.12 (1.13%)
2026-11-12 04:08 CET
Market cap
689.67 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-74.09 USD m
Free cash flow, TTM
-59.37 USD m
EPS diluted, TTM
-1.20
P/E
-
Compare

Price

DSGN against its 20, 50 and 200-day averages
2050200beat
10.0012.0014.0016.003.8M7.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DSGNclose 10.7720-day 10.5550-day 11.88200-day 12.1810.7752w high

37.6% under the 52-week high of 17.25 on 29 Apr 2026. 52-week low 6.81 on 14 Nov 2025. Last 15 sessions, 18.8% high to low

Volume 0.79× normal · the line is the 50-bar volume average

Profile

DSGN
52-week range, 38% of the way up
6.8117.25

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

IndexRUT
Employees124
IPOMar 26, 2021
Beta1.75
ATR, 14d0.66
Rel volume0.79
Short float17.84%
Insider own44.74%
Inst own60.00%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap689.67M
Enterprise Value483.57M
Income-74.09M
Sales0.00M
Book/sh3.17
Cash/sh3.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees124
IPOMar 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.40
P/C3.31
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.78
Current Ratio16.78
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.20
EPS next Y-1.55
EPS next Q-0.40
EPS this Y-8.89%
EPS next Y-16.95%
EPS next 5Y-15.32%
EPS past 3/5Y-2.32% -52.23%
Sales past 3/5Y- -
EPS Y/Y TTM-1.42%
Sales Y/Y TTM-
EPS Q/Q-7.88%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.7.00% -

Ownership

Insider Own44.74%
Insider Trans0.00%
Inst Own60.00%
Inst Trans25.97%
ROA-34.57%
ROE-36.87%
ROIC-36.31%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA202.09%
SMA50-9.33%
SMA200-11.61%
Trades-

Technical

Shs Outstand63.79M
Shs Float35.38M
Short Float17.84%
Short Ratio10.94
Short Interest6.31M
52W High17.25 -37.57%
52W Low6.81 58.15%
Volatility7.52% 6.01%
ATR (14)0.66
RSI (14)48.34
Beta1.75
Rel Volume0.79
Avg Volume577.01K
Volume455,719

Performance

Perf Week1.32%
Perf Month10.12%
Perf Quarter-25.16%
Perf Half Y-31.05%
Perf YTD14.82%
Perf Year38.79%
Perf 3Y435.82%
Perf 5Y-46.92%
Perf 10Y-
Recom1.00
Target Price21.57
Prev Close10.65
Price10.77
Change %1.13%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 02, 2026InitiatedWWells FargoOverweight$26+141.4%
May 12, 2026InitiatedCCantor FitzgeraldOverweight
Mar 16, 2026InitiatedJJefferiesBuy$15+39.3%
Jan 07, 2026InitiatedOOppenheimerOutperform$18+67.1%
Dec 03, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$14+30.0%
Dec 03, 2025InitiatedCCraig HallumBuy$15+39.3%
Nov 20, 2025UpgradeRRBC Capital MktsSector Perform → Outperform$13+20.7%
May 07, 2024UpgradePPiper SandlerNeutral → Overweight$6 → $12+11.4%
Nov 14, 2023DowngradePPiper SandlerOverweight → Neutral$42 → $6-44.3%
Aug 15, 2023DowngradeWWedbushOutperform → Neutral$19 → $6-44.3%

Peers

Mkt cap
TickerCompanyMkt cap
LRMRLarimar Therapeutics Inc283.61M
LXEOLexeo Therapeutics Inc252.01M
DYNDyne Therapeutics Inc3.37B
SLDBSolid Biosciences Inc848.24M
WVEWave Life Sciences Inc674.52M
PEPGPepGen Inc364.31M
TRDAEntrada Therapeutics Inc212.98M
SRPTSarepta Therapeutics Inc1.79B
RAREUltragenyx Pharmaceutical Inc1.70B
STOKStoke Therapeutics Inc1.82B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Logos Global Master Fund LPDirectorNov 18 '25Proposed Sale7.43120,000891,600Nov 18 04:28 PM
Logos Global Master Fund LPDirectorNov 14 '25Proposed Sale7.06620,0004,377,200Nov 14 04:18 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.320-0.344-0.3200.000.007
2026Q22026-08-03-0.320-0.344-0.3230.000.007
2026Q12026-04-28-0.290-0.328-0.2870.000.006
2025Q42026-03-09-0.270-0.354-0.2720.000.005
2025Q32025-11-05-0.300-0.343-0.2980.000.003
2025Q22025-08-07-0.340-0.330-0.3360.000.003
2025Q12025-05-07-0.310-0.280-0.3120.000.003
2024Q42025-03-10-0.240-0.267-0.2410.000.003
2024Q32024-11-07-0.230-0.243-0.2300.000.003
2024Q22024-08-05-0.210-0.233-0.2090.000.003
2024Q12024-05-08-0.200-0.263-0.1970.000.003
2023Q42024-03-19-0.210-0.310-0.2110.000.004
2023Q32023-11-13-0.280-0.408-0.2820.000.004
2023Q22023-08-14-0.360-0.398-0.3560.000.004
2023Q12023-05-09-0.350-0.358-0.3450.000.005
2022Q42023-03-14-0.310-0.344-0.3100.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.320--0.1490.21-
2021FY-0.770-0.800-0.6410.000.00
2022FY-1.140-1.170-1.1360.000.00
2023FY-1.190-1.295-1.1940.000.00
2024FY-0.880-0.900-0.8760.000.00
2025FY-1.220-1.302-1.2200.000.00
2026FY--1.329--0.00
2027FY--1.554--0.00
2028FY--1.871--6.23
2029FY--1.560--63.42
2030FY--0.313--243.19

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-056000.000.000.00
2026Q4S2026-11-046000.000.000.00
2026Q4S2026-10-016000.000.000.00
2026Q4S2026-08-035000.000.000.00
2026Q4S2026-07-225000.000.000.00
2026Q4S2026-05-116000.000.000.00
2026Q4S2026-04-295000.000.000.00
2026Q4S2026-04-135000.000.000.00
2026Q4S2026-03-104000.000.000.00
2026Q4S2025-12-023000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4S2025-11-082000.000.000.00

Estimate history

EPS, annual-0.037-0.149-0.641-1.136-1.194-0.876-1.217-1.2039
Period2019202020212022202320242025TTM
EPS, quarterly-0.23-0.241-0.312-0.336-0.298-0.272-0.287-0.323-0.322
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual55.61755.61755.44255.89656.47456.75460.39863.785
Period2019202020212022202320242025MRQ
Shares, quarterly56.62156.75456.76956.94856.96460.39862.44162.5863.785
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.600.620.600.540.470.130.010.00
Gross Profit-0.60-0.62-0.60-0.54-0.47-0.13-0.010.00
Selling, General and Administrative Excl. Other81.6878.8461.7977.6567.1335.708.552.74
Research and Development60.5258.5143.7556.5348.1524.656.061.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-82.28-79.47-62.38-78.19-67.59-35.83-8.56-2.74
Interest Expense0.000.000.000.000.000.00--
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-74.09-69.79-49.59-66.86-63.31-35.53-8.28-2.05
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-74.09-69.79-49.59-66.86-63.31-35.53-8.28-2.05
Net Income From Continuing Operations-74.09-69.79-49.59-66.86-63.31-35.53-8.28-2.05
Net Income-74.09-69.79-49.59-66.86-63.31-35.53-8.28-2.05
EPS (Recurring)-1.18-1.22-0.88-1.19-1.14-0.64-0.15-0.04
EPS (Basic, Before Extraordinaries)-1.20-1.22-0.88-1.19-1.14-0.64-0.15-0.04
EPS (Diluted)-1.20-1.22-0.88-1.19-1.14-0.64-0.15-0.04
EBITDA-81.68-78.84-61.79-77.65-67.13-35.70-8.55-2.74
Non-Operating Income (Expense)8.209.6812.7911.334.290.300.280.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.2814.5513.0713.0910.934.690.450.00
Shares Outstanding63.7960.4056.7556.4755.9055.4455.6255.62
Market Capitalization689.67689.67349.35148.41573.641,191.731,185.05-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.140.150.160.160.150.150.160.15
Gross Profit-0.14-0.15-0.16-0.16-0.15-0.15-0.16-0.15
Selling, General and Administrative Excl. Other22.0922.0319.5518.0119.1621.4220.2616.55
Research and Development16.7916.2414.2213.2714.4315.5915.2212.01
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.23-22.18-19.71-18.17-19.31-21.57-20.42-16.69
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-20.29-20.16-17.64-16.00-17.00-19.08-17.71-13.65
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.29-20.16-17.64-16.00-17.00-19.08-17.71-13.65
Net Income From Continuing Operations-20.29-20.16-17.64-16.00-17.00-19.08-17.71-13.65
Net Income-20.29-20.16-17.64-16.00-17.00-19.08-17.71-13.65
EPS (Recurring)-0.32-0.32-0.29-0.27-0.30-0.34-0.31-0.24
EPS (Basic, Before Extraordinaries)-0.32-0.32-0.29-0.27-0.30-0.34-0.31-0.24
EPS (Diluted)-0.32-0.32-0.29-0.27-0.30-0.34-0.31-0.24
EBITDA-22.09-22.03-19.55-18.01-19.16-21.42-20.26-16.55
Non-Operating Income (Expense)1.942.012.072.172.312.492.703.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.053.873.923.443.593.983.543.47
Shares Outstanding63.7962.5862.4460.4056.9656.9556.7756.75
Market Capitalization689.67903.75656.19534.32428.82191.31219.10349.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments219.84245.48281.80330.39384.0636.090.08
Short Term Receivables1.681.261.431.110.110.010.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets2.261.301.353.621.260.130.01
Total Current Assets223.78248.04284.58335.12385.4436.230.09
Net Property, Plant & Equipment2.423.634.635.565.120.070.00
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.00---0.000.000.00
Deferred Tax Assets0.55------
Other Assets0.000.430.430.460.000.210.00
Total Assets226.75252.09289.64341.14390.5636.520.09
Short Term Debt Incl. Current Port. of LT Debt0.890.800.720.640.490.000.69
Accounts Payable2.312.191.943.021.620.000.00
Other Current Liabilities9.855.486.977.113.172.333.04
Total Current Liabilities13.058.469.6210.785.282.333.73
Long Term Debt0.651.532.333.053.140.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.55------
Other Liabilities0.000.000.000.000.000.140.00
Total Liabilities14.2510.0011.9613.838.432.483.73
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0045.360.00
Common Equity212.50242.10277.69327.31382.13-11.31-3.64
Total Shareholders Equity212.50242.10277.69327.31382.1334.04-3.64
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity212.50242.10277.69327.31382.1334.04-3.64
Total Liabilities & Stockholders Equity226.75252.09289.64341.14390.5636.520.09
Book Value Per Share3.524.274.925.866.89-0.20-0.07
Tangible Book Value Per Share3.524.274.925.866.89-0.20-0.07
Full-Time Employees124541241323815-
Price to Book Ratio3.401.380.521.683.113.00-
Return on Assets-29.15-18.31-21.20-17.30-16.64-45.24-
Return on Equity-30.70-19.08-22.10-17.85-17.08-54.48-
Return on Invested Capital-32.74-20.35-23.88-19.16-9.22-24.32-
Quick Ratio17.1429.3129.5831.1072.9615.550.02
Current Ratio17.1429.3129.5831.1072.9615.550.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-74.09-69.79-49.59-66.86-63.31-35.53-8.28-2.05
Depreciation0.600.620.600.540.470.130.010.00
Other Funds (Non Cash)14.7611.706.887.049.114.630.420.10
Funds from Operations-58.73-57.47-42.11-59.29-53.74-30.77-7.86-1.95
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.573.11-0.990.731.991.40-0.811.81
Cash from Operating Activities-59.30-54.36-43.10-58.56-51.74-29.38-8.67-0.14
Capital Expenditures-0.07-0.19-0.34-0.26-0.92-1.54-0.080.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.040.000.000.00
Purchase or Sale of Investments-3.8623.1144.3052.79-220.11-52.11-33.480.00
Purchase of Investments-182.43-291.78-230.18-224.70-313.00-86.26-55.590.00
Sale Or Maturity of Investments178.57314.88274.47277.5092.8934.1622.100.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-3.9322.9143.9552.54-220.99-53.64-33.560.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock63.3925.740.510.720.66379.210.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock63.3925.740.510.720.66379.210.000.00
Proceedsfrom Stock Options62.7625.500.480.300.34379.180.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.0044.530.20
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities63.3925.740.510.720.66379.2144.530.20
Net Change in Cash0.16-5.711.36-5.30-272.07296.192.300.06
Free Cash Flow-59.37-54.55-43.45-58.82-52.66-30.91-8.74-0.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments208.61207.40222.82219.84205.97216.28
Short Term Receivables1.741.791.821.681.381.35
Inventories0.000.000.000.000.000.00
Other Current Assets3.612.832.402.261.682.17
Total Current Assets213.96212.01227.05223.78209.03219.79
Net Property, Plant & Equipment2.853.123.392.422.743.09
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---0.55--
Other Assets0.000.000.000.000.000.00
Total Assets216.81215.13230.44226.75211.77222.89
Short Term Debt Incl. Current Port. of LT Debt0.660.630.540.890.870.84
Accounts Payable2.083.142.282.311.911.01
Other Current Liabilities10.027.477.389.858.396.89
Total Current Liabilities12.7511.2410.1913.0511.178.75
Long Term Debt1.862.032.200.650.881.10
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.55--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities14.6113.2712.3914.2512.059.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity202.20201.86218.05212.50199.72213.04
Total Shareholders Equity202.20201.86218.05212.50199.72213.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity202.20201.86218.05212.50199.72213.04
Total Liabilities & Stockholders Equity216.81215.13230.44226.75211.77222.89
Book Value Per Share3.173.233.493.523.513.74
Tangible Book Value Per Share3.173.233.493.523.513.74
Full-Time Employees128--12412357
Price to Book Ratio3.404.143.022.682.010.84
Return on Assets-34.57-32.33-29.80-29.15-28.49-25.78
Return on Equity-36.87-34.13-31.26-30.70-29.83-26.77
Return on Invested Capital-9.94-9.89-8.01-7.51-8.47-8.91
Quick Ratio16.7818.8622.2817.1418.7125.13
Current Ratio16.7818.8622.2817.1418.7125.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.29-20.16-17.64-16.00-17.00-19.08
Depreciation0.140.150.160.160.150.15
Other Funds (Non Cash)4.073.933.852.922.823.50
Funds from Operations-16.08-16.09-13.63-12.93-14.03-15.44
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.700.56-2.800.962.860.99
Cash from Operating Activities-15.38-15.52-16.43-11.97-11.16-14.44
Capital Expenditures-0.01-0.020.00-0.030.00-0.09
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.2015.08-7.59-11.556.5120.20
Purchase of Investments-29.80-12.42-52.59-87.62-78.08-39.53
Sale Or Maturity of Investments30.0027.5045.0076.0884.5859.73
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.1915.06-7.59-11.586.5120.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock17.530.6019.9325.320.040.36
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock17.530.6019.9325.320.040.36
Proceedsfrom Stock Options17.260.4619.9125.140.000.36
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities17.530.6019.9325.320.040.36
Net Change in Cash2.350.14-4.091.77-4.626.04
Free Cash Flow-15.39-15.54-16.43-12.00-11.16-14.53

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.84%6.3M35.4M585.57K
2026-10-1519.24%6.7M34.6M601.84K
2026-09-3019.13%6.6M34.6M655.65K
2026-09-1515.79%5.5M34.6M709.42K
2026-08-3116.05%5.5M34.5M708.26K
2026-08-1417.16%5.9M34.5M915.10K
2026-07-3115.78%6.0M37.7M939.22K
2026-07-1515.06%5.7M37.7M972.34K
2026-06-3015.18%5.7M37.7M870.35K
2026-06-1512.30%4.6M37.7M741.04K
2026-05-2910.30%3.9M37.7M656.11K
2026-05-157.71%2.9M37.7M389.88K
2026-04-306.32%2.3M36.7M329.48K
2026-04-156.17%2.2M36.3M276.00K
2026-03-316.07%2.1M34.3M265.15K
2026-03-135.72%2.0M34.3M327.85K
2026-02-275.49%1.7M31.7M340.48K
2026-02-135.70%1.8M31.7M367.92K
2026-01-306.38%2.0M31.3M425.82K
2026-01-157.41%2.3M31.3M385.04K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call4.004.808.600.0011.8820.000.000.981-0.0160.001
call5.003.807.600.009.5460.000.000.976-0.0160.001
call6.002.906.600.007.8440.000.000.969-0.0150.001
call7.001.905.600.006.4930.000.000.961-0.0140.001
call8.001.004.600.005.3560.000.000.781-0.1550.005
call9.000.053.800.004.7160.000.000.730-0.1470.006
call10.000.002.900.003.9270.000.000.669-0.1420.006
call11.000.002.351.403.69081.000.000.600-0.1360.006
call12.000.002.150.683.90882.000.000.551-0.1470.007
call13.000.002.003.102.7711.000.000.417-0.0970.007
call14.000.001.901.214.5202.000.000.479-0.1630.007
call15.000.001.900.004.6750.000.000.464-0.1760.007
call16.000.001.900.004.9690.000.000.451-0.1870.007
call17.000.001.900.005.2340.000.000.440-0.1960.007
call18.000.001.900.005.4750.000.000.430-0.2040.007
call19.000.001.900.945.6962.000.000.422-0.2120.007
call20.000.001.900.005.9010.000.000.415-0.2180.007
put4.000.001.900.003.5380.000.00-0.019-0.0150.001
put5.000.001.900.002.8090.000.00-0.024-0.0150.001
put6.000.001.900.007.8850.000.00-0.139-0.1610.004
put7.000.001.900.051.70770.000.00-0.039-0.0140.001
put8.000.001.900.005.2860.000.00-0.230-0.1450.005
put9.000.002.000.004.6800.000.00-0.270-0.1460.006
put10.000.002.250.004.1400.000.00-0.331-0.1410.006
put11.000.002.600.003.7370.000.00-0.400-0.1350.006
put12.000.003.300.003.8040.000.00-0.449-0.1460.007
put13.001.504.302.504.24320.000.00-0.489-0.1550.007
put14.001.505.100.004.3220.000.00-0.519-0.1630.007
put15.002.506.100.004.6520.000.00-0.536-0.1750.007
put16.003.507.200.005.0980.000.00-0.549-0.1850.007
put17.004.408.200.005.3650.000.00-0.560-0.1940.007
put18.005.509.200.005.6080.000.00-0.570-0.2020.007
put19.006.4010.200.005.8310.000.00-0.578-0.2100.007
put20.007.5011.200.006.0380.000.00-0.585-0.2160.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-04424B5SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-09SEC
2026-06-09SCHEDULE 13GSEC
2026-05-188-KCurrent report2026-05-18SEC
2026-05-15SCHEDULE 13G/ASEC
2026-04-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-288-KCurrent report2026-04-28SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-23SEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-013Initial statement of beneficial ownership of securities2026-03-31SEC
2026-04-018-KCurrent report2026-03-31SEC
2026-03-11SCHEDULE 13D/ASEC
2026-03-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-0910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-098-KCurrent report2026-03-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SR ONE CAPITAL MANAGEMENT, LP10.45%
Logos Global Management LP4.80%
BAKER BROS. ADVISORS LP4.29%
DRIEHAUS CAPITAL MANAGEMENT LLC4.26%
BlackRock, Inc.4.26%
Point72 Asset Management, L.P.3.79%
Trails Edge Capital Partners, LP3.20%
Frazier Life Sciences Management, L.P.2.90%
Vivo Capital, LLC2.58%
VANGUARD CAPITAL MANAGEMENT LLC2.52%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.86%
iShares Russell 2000 ETF1.31%
Select Biotechnology Portfolio0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.60%
Fidelity Small Cap Index Fund0.54%
iShares Russell 2000 Growth ETF0.46%
iShares Biotechnology ETF0.43%
Fidelity Enhanced Small Cap Core ETF0.33%
VANGUARD RUSSELL 2000 INDEX FUND0.28%
Fidelity Extended Market Index Fund0.25%

OakChart. DSGN. Cached 15 minutes.